What is your approach to continuing or altering therapy when inheriting a patient with combined biologic immunosuppression that is in excess of guidelines?  

How do you approach de-escalation or justify therapy maintenance? Do you have tiers of medications that you attempt to de-escalate first? In one particular case, a patient has Rinvoq, Humira, Actemra, and ibrutinib for a combination of multiple autoimmune and autoinflammatory diagnoses.



Answer from: at Community Practice
Comments
at UTMB Health
I agree with Dr. @DeMarco. It reminds me of a pati...
Sign in or Register to read more